What's Happening?
Gilead Sciences, Inc. is set to present new research findings at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C. The company will showcase data from more than 35 accepted abstracts,
focusing on primary biliary cholangitis (PBC) and viral hepatitis. Key presentations will include late-breaking data on Livdelzi® (seladelpar) for PBC, highlighting its potential to stabilize or improve liver health. Additionally, Gilead will present integrated analyses on bulevirtide for chronic hepatitis delta virus (HDV) and data from the Phase 3 ALLIANCE study on HIV/HBV co-infected participants. The FOCUS program will also be featured, demonstrating innovative approaches to blood-borne virus screening and care linkage.
Why It's Important?
The presentation of these findings underscores Gilead's commitment to advancing treatments for liver diseases, which have significant implications for public health. The data on Livdelzi® and bulevirtide could lead to improved therapeutic options for patients with PBC and HDV, potentially enhancing patient outcomes and quality of life. The FOCUS program's emphasis on strategic partnerships and innovative screening methods highlights the importance of public-private collaboration in addressing viral hepatitis and HIV. These efforts contribute to the broader goal of improving health equity and access to care for vulnerable populations.
What's Next?
Gilead's ongoing research and development efforts in liver disease treatments are expected to continue, with potential regulatory decisions pending for bulevirtide in the U.S. The company is committed to furthering its understanding of liver disease progression and patient experiences, which may lead to new therapeutic strategies and improved patient care. The outcomes of the AFFIRM study and other confirmatory trials will be crucial in determining the continued approval of Livdelzi® in the U.S.
Beyond the Headlines
The Reflecting Realities™ campaign launched by Gilead aims to capture the real experiences of people living with liver conditions, fostering meaningful conversations between patients and healthcare providers. This initiative highlights the emotional and social dimensions of living with liver disease, emphasizing the need for compassionate care and patient-centered approaches.
